Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure Early biomarker signals are consistent with pathway modulation in the brain Teitur is planning to start a Phase II clinical trial of TT-P34 in PD in 2027 Aarhus, Denmark, September 10, […]
Collaboration will evaluate Scenic’s first-in-class PLA2G15 inhibitor program in Parkinson’s disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving lysosomal health as a therapeutic angle for Parkinson’s disease Amsterdam, The Netherlands — 11 June, 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose function‑first genomics engine has […]
Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence Düsseldorf, Germany and Gothenburg, Sweden – 8 July 2025 – Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused […]
Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]
• Developing novel therapeutics which enhance the removal of dysfunctional mitochondria, promoting cell health and function • MTX325 is a potentially disease-modifying treatment for Parkinson’s Disease with clinical trial due to start imminently • Backed by blue chip international investors Cambridge, UK – March 14, 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech […]
